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Abstract
Background: Streptococcus pneumoniae is a common respiratory pathogen and a major causative
agent of respiratory infections, including otitis media (OM). Pneumococcal biofilms have been
demonstrated on biopsies of the middle ear mucosa in children receiving tympanostomy tubes,
supporting the hypothesis that chronic OM may involve biofilm development by pathogenic
bacteria as part of the infectious process. To better understand pneumococcal biofilm formation
six low-passage encapsulated nasopharyngeal isolates of S. pneumoniae were assessed over a six-
eight day period in vitro.
Results: Multiparametric analysis divided the strains into two groups. Those with a high biofilm
forming index (BFI) were structurally complex, exhibited greater lectin colocalization and were
more resistant to azithromycin. Those with a low BFI developed less extensive biofilms and were
more susceptible to azithromycin. dsDNA was present in the S. pneumoniae biofilm matrix in all
strains and treatment with DNase I significantly reduced biofilm biomass. Since capsule expression
has been hypothesized to be associated with decreased biofilm development, we also examined
expression of cpsA, the first gene in the pneumococcal capsule operon. Interestingly, cpsA was
downregulated in biofilms in both high and low BFI strains.
Conclusion: All pneumococcal strains developed biofilms that exhibited extracellular dsDNA in
the biofilm matrix, however strains with a high BFI correlated with greater carbohydrate-associated
structural complexity and antibiotic resistance. Furthermore, all strains of S. pneumoniae showed
downregulation of the cpsA gene during biofilm growth compared to planktonic culture, regardless
of BFI ranking, suggesting downregulation of capsule expression occurs generally during adherent
growth.
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Background
Streptococcus pneumoniae is an important bacterial patho-
gen worldwide that causes localized disease including
pneumonia and otitis media (OM), as well as invasive
infections such as septicemia and meningitis. The ability
of this organism to persist in the respiratory tract and tran-
sition between asymptomatic carriage and infection stim-
ulates intense research interest in S. pneumoniae.
Pneumococcus is a leading bacterial cause of acute OM in
children where it is estimated that by age five, over 80% of
children have had at least one OM episode [1]. S. pneumo-
niae is also frequently detected in chronic otitis media
with effusion (OME) [2], the most common cause of
acquired conductive hearing loss in children. While, inva-
sive disease has decreased with the introduction of the
pneumococcal heptavalent conjugate vaccine (PCV7),
localized infection in the middle ear has not been reduced
as dramatically and new serotypes, some resistant to mul-
tiple antibiotics, have emerged [3,4].
The detection of pneumococcal-specific DNA and RNA in
culture-negative effusions in multiple studies suggests that
active bacterial infections are present more frequently
than culture results indicate [2,5-7], and both the persist-
ence of bacteria and recalcitrance to antibiotic treatment
in OME suggest that chronic OM may be associated with
bacterial biofilm development on the mucosal surface of
the middle ear [7,8]. This hypothesis was recently sup-
ported by evidence of adherent S. pneumoniae,  Haemo-
philus influenzae and Moraxella catarrhalis directly on the
middle-ear mucosal epithelium (MEM) in children receiv-
ing tympanostomy tube (TT) placement for chronic otitis
media [9]. In this study, clusters of adherent pneumococ-
cus were observed on the MEM using 16S rRNA fluores-
cent in situ hybridization (FISH) and anti-pneumococcal
immunostaining. Pathogenic biofilm bacteria were absent
on MEM biopsies from patients undergoing surgery for
cochlear implantation, suggesting that adherent bacteria
are not typically present on MEM.
Biofilm development is initiated when bacterial cells
attach to a surface, proliferate and extrude a complex
extracellular matrix that binds cells together and to a sur-
face. Several chronic infections, such as cystic fibrosis
pneumonia, and chronic tonsillitis and sinusitis, exhibit
biofilm development in the respiratory tract of the human
host [10-14]. Bacteria within biofilms exhibit two funda-
mental characteristics: production of an extracellular pol-
ymeric substance (EPS) matrix and increased resistance to
antimicrobial treatment [11,12]. Depending on the type
of bacteria in the biofilm, the EPS can be made up of
polysaccharides, proteins and DNA [15]. Following
attachment and biofilm development, bacteria may
undergo significant phenotypic shifts including induction
of different metabolic pathways, reduced cell division,
and development of resistance to antibiotic concentra-
tions capable of killing planktonic bacteria [16-19]. Bio-
film formation is important in understanding the extent
of bacterial phenotypic plasticity in response to varying
environmental conditions and several papers have
reported pneumococcal biofilm formation in vitro under
various growth conditions [16,20-26].
The pneumococcal capsule is considered a major viru-
lence factor. Capsule expression is thought to interfere
with biofilm formation [20,23,24,26] and biofilm devel-
opment may select for unencapsulated phenotypic vari-
ants [20,23,26]. However, S. pneumoniae is also known to
phenotypically vary capsule production upon adherence
to epithelial cells [27]. The polysaccharide capsule-spe-
cific regions of S. pneumoniae are encoded by a cluster of
genes located between dexB  upstream and aliA  down-
stream [28] and the capsule is predicted to be transcribed
as a single operon, initiating upstream of the most con-
served gene in the operon, cpsA [29].
We chose a static culture system to examine biofilm for-
mation under conditions that simulate those in the mid-
dle ear during OME. Biofilm development in six
encapsulated clinical strains of S. pneumoniae representing
six different serotypes was assessed by three independent
techniques and statistically analyzed to formulate a para-
metric index of biofilm development that resulted in
ranking the strains into two groups. The index was then
used to test hypotheses concerning pneumococcal bio-
films such as the composition of the extracellular matrix,
susceptibility of pneumococcal biofilms to antimicrobial
treatment and capsule expression using cpsA.
Results
S. pneumoniae clinical strains vary in initial attachment, 
kinetics of biofilm formation and biofilm structural 
complexity and the Biofilm Forming Index (BFI)
Pneumococcal biofilm development was examined in situ
over time for each strain using the BacLight Kit and CLSM.
All isolates developed biofilms over the 6 day period.
However, there was considerable variability in both the
extent and kinetics of biofilm development by the iso-
lates, and in the number of viable and nonviable cells
(Fig. 1). After 24 hours all 6 pneumococcal isolates had
formed heterogeneous biofilms consisting of individual
cells, small chains and small clusters of lancet-shaped cells
with strain BS72 exhibiting the greatest number of
attached cells and a complex biofilm architecture at this
time point consisting of small clusters and towers (data
not shown). By day 3, strains exhibited a range of
ultrastructural characteristics from individual cells and
small microcolonies stippled across the surface (BS68,
BS71 and BS73) to clusters of bacteria in large towers
attached to the substratum (BS69, BS72 and BS75) (dataBMC Microbiology 2008, 8:173 http://www.biomedcentral.com/1471-2180/8/173
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CLSM images of biofilm development by clinical isolates of S. pneumoniae stained with BacLight after 6 days of culture showing  viable (green fluorescence) and nonviable (red fluorescence) pneumococci within the biofilms Figure 1
CLSM images of biofilm development by clinical isolates of S. pneumoniae stained with BacLight after 6 days of 
culture showing viable (green fluorescence) and nonviable (red fluorescence) pneumococci within the biofilms. 
Images are maximum projections or reconstructed confocal stacks consisting of a series of x-y sections. Sideviews (YZ – left 
and XZ – bottom) are saggital sections of the biofilm. Scale bar = 30 μm.BMC Microbiology 2008, 8:173 http://www.biomedcentral.com/1471-2180/8/173
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not shown). Strains BS69, BS72 and BS75 developed the
most extensive biofilm architecture by day 6 of culture,
growing in tall towers of viable cells up to 25 μm in height
over the surface (Fig. 1). Time lapse CLSM imaging
through the thickness of biofilm towers in real time
showed that the towers were free to oscillate indicating
that pneumococcal biofilms were dynamic in the fluid
(see movie at http://centerforgenomicsciences.org/
research/biofilm.html). In contrast, strains BS68, BS71
and BS73 exhibited smaller cell clusters (5–10 μm), fewer
towers and less extensive surface coverage and ultrastruc-
ture. Nevertheless, biofilms formed by these strains exhib-
ited numerous microcolonies of viable cells attached on
the surface.
To better assess biofilm development quantitatively, CFUs
of attached pneumococci were enumerated at 3 time
points to assess the kinetics of biofilm development. Via-
ble adherent pneumococci increased over time in all
strains. Attached viable pneumococci were present for all
clinical isolates at day 1 ranging from 3.1(log10) CFUs/cm2
for BS75 up to 4.9(log10) for BS72 (Fig. 2A). BS75 biofilms
contained significantly fewer culturable cells and BS72
biofilms contained a significantly greater number of cells
than all of the other 5 strains at day 1, confirming CLSM
observation. By day 6, there was a significant difference in
the number of adherent cells among the clinical isolates;
BS69 and BS75 showed the most viable attached pneumo-
cocci with an average CFU/cm2 of 6 and 5.7, respectively.
BS72 averaged 5.4 log10 CFUs/cm2, however the number
of CFUs/cm2 for this strain was not statistically different
from BS68, BS71 or BS73 biofilms, which demonstrated
average viable attached pneumococcus on the order of
5.4, 5.0 and 5.5 log10 CFUs/cm2, respectively. Although
the kinetics of surface attachment varied among clinical
pneumococcal isolates, viable adherent cells increased
over 6 days in all strains.
All 6 clinical isolates also attached over a 24 hour period
(Fig. 2B) demonstrated by crystal violet staining. How-
ever, strains BS69, BS72 and BS75 produced nearly twice
as much biofilm as strains BS68, BS71 and BS73. BS71
formed significantly less biomass than all of the other iso-
lates in this assay (P values < 0.05). There was no signifi-
cant difference between BS72, BS69 and BS75.
Strain differences were also quantified using COMSTAT
(Fig. 2C). Biofilm biovolume (biomass) and maximum
thickness were lower for the clinical strains BS68, BS71
and BS73. Consistent with the experimental results of the
CFU/cm2 and CV assays, BS69 and BS72 exhibited the
greatest extent of total biomass and maximum thickness
(> 20 μm). Surface roughness, a measure of biofilm heter-
ogeneity, was low for these isolates, with greater heteroge-
neity correlating with microcolonies separated by large
voids (data not shown). ANOVA analysis of COMSTAT
data demonstrated significant differences among the
strains with respect to biofilm formation. Comparison of
averages from grouped COMSTAT data (multiple plates,
multiple experiments) demonstrated that BS69 and BS72
exhibited significantly more biomass than the other
strains in this biofilm assay.
When data were combined from all 3 biofilm assays using
the combined biofilm forming index (BFI) metric, the
strains divided into two groups (Fig 2D). Strains BS69,
BS72 and BS75 demonstrated far greater biofilm develop-
ment (in order of ranking), while strains BS68, BS71 and
BS73 demonstrated less biofilm development.
Scanning electron microscopy (SEM) comparison of two S. 
pneumoniae isolates
BS69 and BS73 were further examined to assess a high and
a low ranked BFI isolate, using high resolution SEM. Fig-
ure 3A shows more widespread surface coverage by the
high ranked BFI isolate, BS69 compared with BS73 and
higher resolution images of the isolates showed BS69 cells
surrounded by extensive extracellular material, anchoring
pneumococcal cells to the surface. In contrast, SEM
showed numerous punctate microcolonies attached over
the surface in the low ranked BFI biofilm isolate, BS73.
Thus, SEM results confirmed that these two isolates dif-
fered in the number of attached cells, but also in the extent
of extracellular material attached to the surface.
S. pneumoniae biofilms demonstrate a carbohydrate 
matrix
The multilayered S. pneumoniae biofilm towers of BS69,
BS72 and BS75 observed with CLSM and SEM suggested
that biofilm towers were held together by an extracellular
matrix. Since fixation for SEM dehydrates the biofilm and
collapses the matrix, we further tested pneumococcal bio-
films for extracellular carbohydrate using a cocktail of 5
fluorescently-conjugated lectins and the nucleic acid
probe, Syto59 under hydrated conditions. Figure 3B
shows biofilms of each pneumococcal isolate grown for 8
days. High ranked BFI isolates (BS69, BS72 and BS75)
exhibited a much greater degree of lectin binding, whereas
low ranked BFI isolates BS71 and BS73 exhibited less lec-
tin binding. BS68 showed more biofilm ultrastructure
using the combination of lectins and Syto 59 than the
other low ranked BFI strains, exhibiting some clusters
stained with nucleic acid stain with large discrete patches
bound with lectin, however the clusters were uniformly
smaller than those of high ranked BFI strains (Fig. 3B).
Biofilms of the unencapsulated strain, R6, also bound lec-
tin. Colocalization of lectin and nucleic acid binding dif-
fered between strains when biofilms were evaluated with
Imaris Colocalization software, using regression analysis
(r2  values). Averages of Pearson's coefficient showedBMC Microbiology 2008, 8:173 http://www.biomedcentral.com/1471-2180/8/173
Page 5 of 16
(page number not for citation purposes)
Figure 2 (see legend on next page)
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greater colocalization of nucleic acid and carbohydrate
specific probes with biofilms of BS69, BS72 and BS75 (Rr
> 0.75) than BS68, BS71 and BS73 (Rr < 0.70), consistent
with lectin binding correlating with higher order biofilm
ultrastructure. High ranked BFI strains significantly dif-
fered from low ranked strains (P < 0.05).
S. pneumoniae biofilms exhibit increased resistance to 
antibiotic treatment
To interrogate another fundamental feature of biofilm
growth, pneumococcal isolates were tested for antibiotic
resistance. Growth of planktonic pneumococci from each
strain was inhibited (demonstrated by no turbidity in the
culture wells compared to wells containing no antibiotic)
by a concentration of 2 μg ml-1 azithromycin. In contrast,
6 day biofilms of these strains required concentrations
from 2 to 1000 fold higher to demonstrate growth inhibi-
tion by azithromycin (no turbidity) (Table 1). High
ranked BFI isolates, BS69, BS72 and BS75, exhibited a 64,
1000 and 32-fold increase in the azithromycin concentra-
tion necessary to achieve no turbidity, indicating BFI cor-
related with increased resistance to antibiotic inhibition
of bacterial outgrowth from biofilms. In situ assessment of
6 day biofilms treated with 20 μg ml-1 of azithromycin for
24 hours further showed that all strains demonstrated via-
ble cells after treatment, but high ranked BFI strains, BS69
and BS72, exhibited viable cells in large attached cellular
clusters with few red cells (Fig. 3C). In contrast, azithro-
mycin treatment of the low ranked BFI strains (BS71 and
BS73) showed only a few viable attached cells.
S. pneumoniae clinical isolates have extracellular DNA in 
the matrix which is degraded with DNAse treatment
To further examine the composition of the pneumococcal
biofilm matrix, biofilms were stained with PicoGreen and
the nucleic acid dye, Syto 59. Figure 4A indicates that
dsDNA is present extracellularly in the biofilm matrix for
strains BS69 and BS73. To confirm the presence of extra-
cellular DNA, when pneumococcal biofilms were treated
with Pulmozyme® (recombinant human DNase I) a signif-
icant loss of cells and biomass was observed (Fig. 4B). Bio-
film degradation following Pulmozyme® treatments was
quantified using COMSTAT and results demonstrate that
the biomass and average thickness of biofilms of all
strains were significantly reduced by DNase treatment in a
dose responsive manner (Fig. 4B). This was true for all
strains regardless of their BFI, with the highest concentra-
tion of DNase resulting in reductions of over 90% in the
average thickness of all strains except BS75 (Table 2).
However, maximum thickness was less affected by DNase
treatment in all of the strains, suggesting that the EPS
matrix in biofilm towers consisted of non-DNA compo-
nents.
CpsA expression is downregulated in pneumococcal 
biofilms
To investigate whether pneumococci in biofilms were
encapsulated we examined cpsA expression under plank-
tonic and biofilm growth conditions in 4 of the isolates (2
high ranked and 2 low ranked BFI strains) to see if capsule
production was modulated during biofilm development.
(All strains grown under planktonic conditions were con-
firmed to be positive for capsule by the Quellung (agglu-
tination) reaction.) All planktonic grown encapsulated
clinical isolates expressed more cpsA (~100 fold) than the
unencapsulated R6 strain (Fig. 5A). However, expression
of  cpsA  was downregulated in the biofilm relative to
planktonic growth conditions in all strains, regardless of
serotype or BFI. Expression of cpsA was higher overall in
strains with a high BFI (BS69 and BS72) compared to low
ranked strains (BS71 and BS73) with the relative fold
reduction 6.3, 7.1, 10 and 7.7, respectively, indicating that
BS71 exhibited the most extensive downregulation. In situ
examination of biofilm-grown isolates using immunoflu-
orescence with type-specific capsule (Fig. 5B) indicated
that capsule-specific antibody binding was brightest in
biofilm towers suggesting that pneumococci attached to
the surface have a reduced amount of capsule. Taken
together these results suggest that capsule expression
undergoes complex modulation during biofilm growth.
Quantitative assessment of biofilm development by clinical pneumococcal isolates Figure 2 (see previous page)
Quantitative assessment of biofilm development by clinical pneumococcal isolates. Fig. 2A. Biofilm development 
by clinical isolates at days 1, 3 and 6 of culture on polystyrene plates as shown by viable adherent cells (CFUs/cm2). Points rep-
resent an average of three duplicate wells per time point in two independent experiments. Error bars represent SD. Fig. 2B. 
Biofilm development (initial attachment) assayed by crystal violet absorbance comparing 6 clinical pneumococcal isolates on 
polystyrene over 24 hours. Bars show average triplicate samples of 5 independent experiments. Bars represent SD. Fig. 2C. 
COMSTAT assessment of pneumococcal biofilm development after 6 days of culture. Two parameters of surface attached 
pneumococci are shown: maximum thickness (biofilm towers) (left axis) and biomass (biofilm volume) (right axis). Bars repre-
sent an average of 3–5 images taken from duplicate plates in 2 independent experiments (minimum n = 12). Error bars repre-
sent standard error of the mean. Fig. 2D. Biofilm forming index (BFI) of the 6 pneumococcal clinical strains (serotype in 
parentheses) combining statistical analyses from the widely used biofilm assays: CFU/cm2, CV assay and COMSTAT analysis. 
The index ranks each strain according to biofilm formation.BMC Microbiology 2008, 8:173 http://www.biomedcentral.com/1471-2180/8/173
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Figure 3 (see legend on next page)
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Discussion
The ability of upper respiratory pathogens including S.
pneumoniae  to persist in the nasopharynx and cause
chronic disease upon the appropriate conditions may be
associated with the ability to form biofilms on mucosal
epithelium [7-9]. The presence of structurally complex
bacterial biofilms is important because biofilms have
been shown to exhibit increased resistance to host
immune effectors and increased tolerance to antibiotic
treatment [11,12,15], and therefore suggest that biofilms
may contribute to the persistence of pathogens.
Previous reports have shown that S. pneumoniae can form
biofilms in vitro using several different models of biofilm
culture [16,20-26] including a study where CSLM data
suggested that some of the strains used in the present
study differed according to structural complexity [16].
Moreover in a pair of companion studies we have demon-
strated that these strains have vastly different genomic
complements [30] and produce significantly different dis-
ease phenotypes in an animal model of infection [31]. We
therefore wished to further characterize biofilm formation
of 6 of these pneumococcal strains by investigating the
kinetics of biofilm formation, biofilm matrix composi-
tion, antibiotic resistance and capsule expression.
All clinical isolates developed biofilms containing viable,
adherent cells over time under static conditions in vitro.
However, biofilm development was highly variable
among the different isolates. A multiparameter ranking,
formulated to compare biofilm formation among the
clinical strains using 3 standard assays commonly used to
measure biofilm formation, identified two groups: those
with a high biofilm forming index (BFI); BS69, BS72 and
BS75, which attached quickly and produced more biofilm
than the other strains, and those with a low BFI; BS68,
BS71 and BS73 which produced biofilms consisting of
adherent cells in small cell clusters with few towers. Our
study suggests that a multi-assay approach for the quanti-
fication of biofilm formation better addresses strain to
strain variation in the context of overall biofilm heteroge-
neity. Bacteria are frequently categorized as being positive
or negative for biofilm formation typically using only a
single assay such as crystal violet staining. However, our
study suggests that such a binary distinction may lead to
an oversimplified conclusion. Clearly, each of the six
strains formed biofilms, but to different degrees. In the
absence of clinical data correlating the degree of in vitro
biofilm formation with infection severity and history, a
biofilm etiology, even for a poor in vitro biofilm forming
strain, should not necessarily be discounted. Not only was
the BFI a useful construct to provide a clearer picture of
Investigation of EPS matrix and antibiotic resistance in pneumococcal biofilms Figure 3 (see previous page)
Investigation of EPS matrix and antibiotic resistance in pneumococcal biofilms. 3A Scanning electron microscopy 
of pneumococcal biofilms on polystyrene by BS69 (a high BFI strain) and BS73 (a low BFI strain) showing cluster morphology 
and evidence of extracellular matrix. Extracellular material can be seen on higher magnification in both clinical isolates, how-
ever more matrix material is visible with BS69 compared with BS73. Areas of extracellular material can be seen tethering S. 
pneumoniae cells to the surface (arrows). Scale bar = 10 μm and 2 μm. Fig. 3B. Strain variability in EPS distribution of pneumo-
coccal biofilms by different clinical isolates demonstrated by lectin binding. Lectin (green fluorescence) and Syto 59 (red fluo-
rescence) indicate binding of probes to carbohydrate or nucleic acid, respectively. Yellow indicates co-localization of the two 
probes. Images are maximum projections or reconstructed confocal stacks consisting of a series of x-y sections. Scale bar = 10 
μm. Fig. 3C. Pneumococcal biofilms treated with azithromycin. High ranked BFI strains (BS69 and BS72) show large cell clus-
ters still viable with the BacLight LIVE/DEAD stain after 24 hours of antibiotic treatment. Low ranked BFI isolates (BS71 and 
BS73) on the other hand, show only a few viable attached cells (Scale bar = 8 μm.).
Table 1: Concentration of antibiotic producing no turbidity after azithromycin treatment for S. pneumoniae clinical isolates grown in 
planktonic culture and as biofilms treated with a twofold serial dilution of azithromycin from 2 mg ml-1 to 2 μg ml-1 for 24 hours.
S. pneumoniae isolate Serotype Planktonic IC* (μg ml-1) Biofilm IC† (μg ml-1) Fold Increase (-) n
BS 68 9V < 2 4 > 2 6
BS 69+ 14 < 2 125 > 64 8
BS 71 3 < 2 4 > 2 6
BS 72+ 23F < 2 2000 > 1000 6
BS 73 6A < 2 4 > 2 6
BS 75+ 19F < 2 62 > 32 8
* Highest concentration of azithromycin producing no turbidity after overnight incubation with antibiotic with planktonic cells.
† Highest concentration producing no turbidity after overnight incubation with antibiotic with biofilm cells.
Turbidity was scored by eye as well as by determining the highest concentration that was within the standard deviation of the optical density 
measurements of 6–8 replicate untreated controls (no antibiotic).
+ Indicates high ranked BFI strain.BMC Microbiology 2008, 8:173 http://www.biomedcentral.com/1471-2180/8/173
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DNA staining of the pneumococcal EPS matrix and disruption with DNase Figure 4
DNA staining of the pneumococcal EPS matrix and disruption with DNase. Fig. 4A. Biofilms stained with 
PicoGreen, a dsDNA stain, and Syto 59 shows that S. pneumoniae biofilms treated with 1000 μg ml-1 Pulmozyme (+) were sub-
stantially reduced compared to untreated biofilms (-) in both high and low BFI strains. Scale bar = 30 μm. Figure 4B. Quanti-
fication of reduction in biofilm volume (total biomass) measured by COMSTAT upon treatment with different concentrations 
of Pulmozyme: Untreated controls ; 1 μg ml-1 Pulmozyme -; 100 μg ml-1 Pulmozyme ▧; 1000 μg ml-1 Pulmozyme ■. Bars 
show average of PicoGreen signal, which stains extracellular dsDNA, and Syto59, which stains intracellular nucleic acid. (Error 
bars represent standard error of the mean; n = 10; 5 randomly chosen microscopic fields from duplicate experiments. *Signifi-
cantly different from untreated controls (P values < 0.05); ** (P values < 0.01). Statistical comparisons were made using one-
way analysis of variance (ANOVA) (Excel 2000, Microsoft).
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the relative biofilm forming capacity of each strain, but it
was also useful in testing putative biofilm characteristics,
since a higher BFI correlated with greater binding with car-
bohydrate-specific lectins and antibiotic resistance in vitro.
Since SEM suggested that BFI was associated with biofilm
structural complexity, biofilms from each pneumococcal
strain were assessed for the presence of carbohydrate in
the EPS matrix using lectin binding. High BFI strains
(BS69, BS72 and BS75) exhibited the most lectin co-local-
ization with the EPS matrix, while strains with a low BFI
(BS71 and BS73) demonstrated reduced lectin co-locali-
zation, suggesting that polysaccharide is associated with
larger multilayered aggregates of attached cells. BS68
exhibited some biofilm towers associated with nucleic
acid and larger discrete patches of lectin binding (suggest-
ing carbohydrate) than other low BFI strains. Lectin bind-
ing did not necessarily correlate with the pneumococcal
capsule, since an unencapsulated strain (R6) which
formed good biofilms, also bound lectin, suggesting that
carbohydrate is associated with noncapsular EPS.
We further assessed another hallmark of biofilm develop-
ment; antibiotic resistance. Six day pneumococcal bio-
films with a low BFI exhibited a 2-fold increase in
resistance to azithromycin compared to planktonic
growth. However, strains with a high BFI required signifi-
cantly higher concentrations to inhibit outgrowth from
biofilms. In situ examination of 6 day biofilms treated
with 20 μg ml-1 of azithromycin (a concentration that was
bactericidal for S. pneumoniae in epithelial cell culture)
[32] showed large clusters of viable bacteria in high
ranked BFI strains. Few viable attached cells were observed
after azithromycin treatment in low ranked isolates.
Although our study did not reflect a standardized mini-
mum inhibitory concentration on biofilm bacteria due to
the difficulty of assessing cell density within biofilms,
these results support the hypothesis that biofilm-forming
pneumococcal strains can persist in spite of antibiotic
treatment and may contribute to chronic infection.
The presence of extracellular DNA (eDNA) in biofilms is
now well documented in several types of bacterial bio-
Table 2: Degradation of S. pneumoniae Biofilms with DNase treatment.
Strain Pulmozyme concentration [% Reduction†]
0 (μg ml-1)1  ( μg ml-1) 100 (μg ml-1) 1000 (μg ml-1)
Biomass (μm3/μm2)
Low BFI
BS68 (9V) 0.20 (0.024) 0.08 (0.005)** 0.04 (0.003)** 0.01 (0.001)** [95.0]
BS71 (3) 0.11(0.013) 0.03 (0.004)** 0.022 (0.005)** 0.02 (0.007)** [81.8]
BS73 (6A) 0.51(0.065) 0.19 (0.019)** 0.08 (0.008)** 0.04 (0.003)** [92.2]
High BFI
BS69 (14) 0.59 (0.126) 0.26 (0.039)* 0.19 (0.020)** 0.14 (0.021)** [76.3]
BS72 (23F) 2.97 (0.278) 1.50 (0.190)** 0.63 (0.083)** 0.24 (0.027)** [92.0]
BS75 (19F) 0.42 (0.041) 0.38 (0.028) 0.18 (0.020) ** 0.14 (0.017)** [66.7]
Average thickness (μm)
Low BFI
BS68 (9V) 0.23 (0.032) 0.08 (0.006)** 0.03 (0.003)** 0.01 (0.002)** [95.7]
BS71 (3) 0.19 (0.048) 0.03 (0.017)** 0.003 (0.000)** 0.004 (0.001)** [94.7]
BS73 (6A) 0.46 (0.068) 0.16 (0.020)** 0.04 (0.005)** 0.02 (0.002)** [95.7]
High BFI
BS 69 (14) 0.46 (0.068) 0.16 (0.020)** 0.04 (0.005)** 0.02 (0.002)** [91.3]
BS72 (23F) 5.23 (0.567) 2.23 (0.404)** 0.43 (0.073)** 0.15 (0.027)** [97.1]
BS75 (19F) 0.39 (0.039) 0.26 (0.024)** 0.12 (0.017)** 0.058 (0.006)** [85.1]
Maximum thickness (μm)
Low BFI
BS68 (9V) 3.6 (0.147) 3.23 (0.091) 2.44 (0.112)** 2.72 (0.275)** [24.4]
BS71 (3) 5.2 (0.169) 3.72 (0.219)** 2.32 (0.099)** 2.00 (0.148)** [61.5]
BS73 (6A) 5.28 (0.249) 3.2 (0.082)** 2.56 (0.110)** 2.56 (0.073)** [51.5]
High BFI
BS 69 (14) 7.12 (0.301) 4.72 (0.343)** 4.24 (0.193)** 3.6 (0.159)** [49.4]
BS72 (23F) 10.08 (0.653) 4.96 (0.331)** 3.36 (0.160)** 3.68 (0.309)** [63.5]
BS75 (19F) 4.20 (0.265) 3.84 (0.198) 3.04 (0.110)** 2.24 (0.110)** [44.3]
Value = average (n = 10)
†Percent reduction of biofilm with highest dose of Pulmozyme.
(Standard error) * p < 0.05; ** p < 0.01BMC Microbiology 2008, 8:173 http://www.biomedcentral.com/1471-2180/8/173
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films including non-typeable H. influenzae, another major
pathogen associated with chronic OM [33-36]. We there-
fore investigated if eDNA was present in the pneumococ-
cal biofilm matrix. All strains showed evidence of eDNA
shown by in situ staining of the matrix with the dsDNA
stain, PicoGreen, and by a dose-dependent reduction of
the pneumococcal biofilm biomass by recombinant
human DNase I treatment using Pulmozyme® (dornase
alfa), used clinically to treat cystic fibrosis pneumonia.
DNase-treated biofilms were significantly reduced in all
pneumococcal strains when treated with the clinical dose
of Pulmozyme® (1 mg ml-1), exceeding 90% reduction in
all but one strain. These results agree with those of Mos-
coso et al. who showed that DNase treatment reduced bio-
films of the unencapsulated S. pneumoniae strain R6, and
are consistent with the ability of S. pneumoniae to autolyse
and release DNA [24,35].
Other in vitro studies with pneumococci have shown that
capsule expression was associated with decreased biofilm
Capsule expression during biofilm growth conditions in selected strains Figure 5
Capsule expression during biofilm growth conditions in selected strains. Fig. 5A. cpsA, the first gene in the pneumo-
coccal capsule operon is expressed in each isolate over 100-fold relative to R6, an unencapsulated strain (hatched bars), but is 
downregulated when pneumococcal strains are grown as biofilms (solid bars). Fig. 5B. Immunostaining with anti-capsule spe-
cific antibody labeled with a secondary Texas red anti-rabbit antibody, shows that pneumococci express type specific capsule in 
the biofilm despite cpsA downregulation. Scale bar = 10 μm.
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formation [20,23,24,26] and some have reported that
biofilm development may select for unencapsulated phe-
notypic variants [20,24,26]. However, S. pneumoniae is
also known to phenotypically vary capsule production
upon adherence to epithelial cells [27]. Therefore we
hypothesized that the capsule operon might be downreg-
ulated in pneumococcal biofilms. Real time-qPCR results
indicate that cpsA is downregulated in the biofilm up to
10-fold depending on the strain, compared to planktonic
cultures regardless of the strain's BFI, suggesting that cap-
sule production is variably modulated during sessile
growth. In situ immunofluorescence staining with anti-
capsule type-specific antibody further demonstrated that
S. pneumoniae growing in biofilms was encapsulated and
capsule immunostaining was brightest in biofilm towers
compared to adherent cells. These results support the role
of cpsA in capsule production [37,38]. Numerous reports
demonstrate capsule phenotypic variation and show that
variants with greater amounts of capsule colonize epithe-
lial cells less efficiently [39-44]. Phenotypic variation of
the capsule has been demonstrated microscopically dur-
ing the initial stages of infection where adherent or inva-
sive S. pneumoniae exhibited reduced amounts of capsule
compared to cells not associated with epithelial cells [27].
Our results showing downregulation of cpsA in pneumo-
coccal biofilms are consistent with observations that S.
pneumoniae modulates capsule production upon adher-
ence.
Conclusion
Biofilm growth differed among six clinical isolates of S.
pneumoniae. A multi-parametric assessment grouped iso-
lates into two categories: those with a high biofilm form-
ing index, which exhibited complex ultrastructure
consisting of large multilayered biofilm towers; and those
with a low BFI, which exhibited small compact microcol-
onies. BFI correlated with increased lectin binding and
resistance to azithromycin. BFI did not correlate with the
presence of DNA in biofilm EPS or modulation of capsule
expression. DNase treatment resulted in a significant
reduction of pneumococcal biofilms in all strains, how-
ever lectin binding to biofilm towers suggests the pneu-
mococcal biofilm matrix is made up of both carbohydrate
and DNA. Finally, cpsA was downregulated in all biofilm
grown strains suggesting that capsule expression is pheno-
typically regulated upon biofilm development.
Methods
Isolation of strains and growth conditions
Clinical isolates of S. pneumoniae used in this study were
obtained from nasal washes from symptomatic pediatric
patients participating in a vaccine trial at Children's Hos-
pital of Pittsburgh and isolated, cultured, serotyped and
frozen as described previously [45]. All clinical isolates
were encapsulated and were cultured identically. The six
strains were: BS68 (serotype 9V); BS69 (serotype 14);
BS71 (serotype 3); BS72 (serotype 23F); BS73 (serotype
6A); and BS75 (serotype 19F). Frozen stocks of S. pneumo-
niae were plated and individual colonies were picked and
grown in THB to an optical density corresponding to 108
cells ml-1. Growth curves were obtained for each strain
and OD and CFUs ml-1 were correlated using regression
analysis. Calibration curves for 1 × 108 CFUs ml-1 and OD
were used to estimate the inoculated number of S. pneu-
moniae  cells and validated by plating as follows: BS68
(OD600 0.03); BS69 (OD600 0.04); BS71 (OD600 0.07);
BS72 (OD600 0.03); BS73 (OD600 0.04) and BS75 (OD600
0.06). All experiments were carried out at 37°C, 5% CO2.
Crystal violet assay for initial biofilm attachment
1 × 107 S. pneumoniae in THB were inoculated into 48-well
plates (Corning, Lowell, MA), incubated for 24 hours and
rinsed to remove non-adherent cells. One ml of 0.5% crys-
tal violet (CV) solution (Sigma Aldrich) was added [31]
and read at 600 nm using a Beckman DU 650 spectropho-
tometer (Beckman Coulter Inc., Fullerton, CA.). Back-
ground absorbance from medium blanks was subtracted
from the values of triplicate samples from 5 independent
experiments.
Biofilm growth
1 × 108 ml-1 S. pneumoniae was inoculated into MatTek cul-
ture plates (MatTek Corporation, Ashland, MA) or 6-well
tissue culture plates (Falcon) and allowed to adhere over-
night. S. pneumoniae biofilms were grown for 1, 3 and 6
days and culture medium was replaced daily with fresh,
warm 1/5 strength THB. For colony forming unit (CFU)
enumeration, S. pneumoniae biofilms were rinsed thrice
with THB and adherent bacteria were detached using a cell
scraper (Corning). One plate was harvested per time point
and duplicate wells were combined (3 per 6 well plate),
vortexed, diluted and plated in 2 independent experi-
ments.
Confocal Laser Scanning Microscopy
Pneumococcal biofilms were also visualized directly using
CLSM and the BacLight Bacterial Viability Kit. Biofilms
were grown for 1, 3, and 6 days and stained according to
the manufacturer's directions, rinsed, immersed in Hank's
balanced salt solution (HBSS) with Ca+2 and Mg+2 and
immediately examined with a Leica DM RXE microscope
attached to a TCS SP2 AOBS confocal system (Leica Micro-
systems, Exton, PA) using a 63× water immersion lens and
the sequential scanning mode. Images were analyzed
using the Leica LCS software, COMSTAT [46] and Imaris
Software (Bitplane; St. Paul, MN).
Scanning electron microscopy (SEM)
Biofilms were processed for SEM by dehydration in a
graded ethanol series. Samples were sputter coated withBMC Microbiology 2008, 8:173 http://www.biomedcentral.com/1471-2180/8/173
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200 angstroms of gold using a Hummer VII Sputtering
System (Anatech Ltd., Alexandria, VA), visualized at an
accelerator voltage of 5 kV using a Tescan Mira field emis-
sion scanning electron microscope (Tescan USA, Cran-
berry Township, PA) and digitized TIFF images were
collected.
EPS Carbohydrate binding with fluorescent lectin probes
To assess the extent and distribution of carbohydrate in
the pneumococcal biofilm matrix, cultures were grown for
8 days as above, rinsed and stained with a cocktail of 5
lectins consisting of Alexa 488-conjugated lectins (Invitro-
gen) at the following concentrations: 50 μg ml-1 of Canav-
alia ensiformis (Con A) specific for α-mannopyranosyl and
α-glucopyranosyl residues, 125 μg ml-1 of (Wheat germ
agglutinin) WGA specific for N-acetyl glucosamine and N-
acetylneuraminic acid, 100 μg ml-1 of Griffonia simplicifolia
(GS II), specific for terminal α- and β- linked N-acetyl-D-
glucosaminyl residues; 125 μg ml-1 of (Soybean aggluti-
nin) SBA, specific for terminal β-galactose; and 75 μg ml-
1 of (Peanut agglutinin) PNA, specific for terminal α- and
β-N-acetyl-galactosamine and galactopyranosyl residues
in HBSS. Three μl of Syto 59 nucleic acid stain was added
per ml of the cocktail. Cultures were stained for 35 min-
utes rinsed to remove unbound lectin and nucleic acid
probe and sequentially scanned using the 488 and 633
nm laser lines to minimize channel cross-talk for co-local-
ization analysis.
COMSTAT image analysis
Quantitative analyses of the CLSM images by the COM-
STAT computer software was performed on day 6 biofilms
stained with BacLight [46], or with PicoGreen, a dsDNA
stain [33] as described. The biofilm parameters, biomass
(biovolume), maximum and average thickness, and
roughness coefficient (an indicator of biofilm heterogene-
ity) were assessed using a minimum of 5 different images
per plate from 2 independent experiments for each iso-
late.
Statistical analyis
Statistical comparisons were made using one-way analysis
of variance (ANOVA) (Excel 2000, Microsoft). Differences
were reported statistically significant for P < 0.05.
Calculation of a "biofilm forming index" (BFI)
To combine the information from the 3 biofilm assays
(crystal violet, 6 day CFU/cm2 count and COMSTAT data)
to give an overall assessment of the degree of biofilm for-
mation of each pneumococcal strain, we used a simple
normalized ranking system based on a "biofilm forming
index" (BFI) for each assay. The Shapiro-Wilk normality
test (The R Project for Statistical Computing: R statistical
software version 2.6.2 (2008 02 08) freely available at
http://www.r-project.org) was used to determine whether
the data sets needed to be transformed to achieve a nor-
mal distribution (P > 0.05). Of the data sets for the 6
pneumococcal strains, 4 of 6 were normal for the CV assay
and viable cell count, and 1 of 6 was normal for COM-
STAT. Log10 transformation of the data resulted in all data
sets conforming to a normal distribution (P > 0.05). The
BFI for each of the individual assays for each of the six
strains was determined using:
BFIOD or BFICFU or BFICOMSTAT = (Log(10) Strain value - 
Log(10) lowest value)/(Log(10) highest value - Log(10) lowest 
value) (1)
Thus each strain was assigned a value ranging from "I", for
the least biofilm, to "1" for the most biofilm.
The data from the 3 assays was combined to find the over-
all combined (BFI) from:
BFI = (BFIOD + BFICFU + BFICOMSTAT)/3 (2)
Antibiotic treatment of S. pneumoniae planktonic cells 
and biofilms
Planktonic cultures were grown to mid-log phase and
incubated with twofold dilutions of azithromycin ranging
from a concentration of 2 mg ml-1 to 2 μg ml-1 in 1/5 THB
for 24 hours in 24-well polystyrene plates (BD, Franklin
Lakes, NJ). Biofilms were grown in 24-well plates for 6
days whereby non-adherent cells were removed to a new
24 well plate and incubated with twofold dilutions of azi-
thromycin to test if nonattached cells at this period of cul-
ture were resistant to azithromycin. Spectrophotometric
readings were taken at 595 nm using a GENios plate
reader and also scored visually. The concentration of azi-
thromycin that showed a lack of turbidity corresponding
to the spectrophotometric reading of the negative control
(THB only) was interpreted as indicating the minimum
concentration of antibiotic that inhibited bacterial
growth. Biofilms were exposed to identical concentrations
of azithromycin and incubated as for planktonic cells;
rinsed with THB and incubated for a further 24 hours. Vis-
ual and spectrophotometric readings of duplicate wells
were taken in 3 different experiments and the lowest con-
centration that indicated no turbidity (inhibition of
planktonic growth from the biofilm or 'showering') was
interpreted as the minimum concentration of antibiotic
that inhibited bacterial outgrowth from the biofilm. Addi-
tionally, S. pneumoniae biofilms were grown in MatTek
plates for 6 days, rinsed and treated with 20 μg ml-1 of azi-
thromycin for 24 h [32], stained with BacLight kit and
imaged in situ.
Pulmozyme® (DNase 1) experiments
Six day biofilms for each strain were incubated for 15
minutes at RT in the dark with Pulmozyme® (dornaseBMC Microbiology 2008, 8:173 http://www.biomedcentral.com/1471-2180/8/173
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alfa), a synthetic DNase I (supplied as 1 mg ml-1 solution),
(Genentech Inc, San Franscisco, CA) in duplicate at each
of three concentrations (1 μg ml-1, 100 μg ml-1 and 1 mg
ml-1). Untreated controls were incubated with 200 μl of
buffer alone (8.7 mg ml-1  NaCl-0.15 mg ml-1CaCl2).
Plates were rinsed and stained for 15 minutes with 100 μl
each of PicoGreen (1 μl ml-1) and Syto 59 (3 μl ml-1) (Inv-
itrogen) [36] in HBSS, rinsed and imaged.
Isolation of RNA
To assess capsular gene expression in clinical isolates, real-
time quantitative PCR (RT-qPCR) was used to measure
the transcripts of the pneumococcal capsular gene, cpsA
[29]. For the isolation of RNA, BS69, BS71, BS72 and
BS73 and the unencapsulated strain R6, were grown to
late log phase (planktonic) or harvested from 6-well
plates after 6 days (biofilm). Total cellular RNA was then
isolated as previously described [47]. RNA preparations
were tested for contaminating DNA by no-reverse-tran-
scriptase PCR reactions.
Real-time quantitative PCR
Oligonucleotide primers and TaqMan probes (Fam-
labeled TaqMan TAMRA probes) used for RT-qPCR were
designed with Primer Express 2.0 software (ABI Prism; PE
Biosystems, Framingham, MA.) to amplify gene fragments
with an optimal size of 60–130 bp. Sequences of primer
sets and corresponding probes used are listed in Table 3.
Measurements of relative levels of gene expression were
done by RT-qPCR as described [47].
PCR reactions were done in 15 μl reaction volumes con-
taining the reaction mixtures as follows: 1.5 μl cDNA; 7.5
μl universal PCR master mix; 1.2 μl forward primer (800
pM); 1.2 μl reverse primer (800 pM); 1.2 μl Taqman probe
(160 pM) and 2.4 μl nuclease-free de-ionized H2O. PCR
amplification parameters were as follows: 50°C for 2 min-
utes, followed by 95°C for 10 minutes, and then 45 cycles
of 95°C for 15 s and 60°C for 1 minute. All qPCR reac-
tions were done in triplicate and the mean CT was used for
analysis of results. The constitutively expressed gene for
DNA gyrase (gyr) was used as an endogenous control as
described previously [25]. The ΔCT  values were deter-
mined by subtracting the gyr CT value from the gene-spe-
cific CT  values. The ΔΔCT  value was calculated by
subtracting the ΔCT value obtained with the ΔCT calibrator
value. To verify the absence of contaminating DNA, each
RT-qPCR experiment included controls that lacked tem-
plate cDNA or reverse transcriptase. The amount of target
gene transcript was expressed as the difference (n-fold)
from the amount of the control gene (2-ΔCT), where ΔCT
represents the difference in threshold cycle between the
target and control genes. Analysis of expression of each
gene was done based on at least 2 independent experi-
ments. Twofold or higher changes in gene expression were
considered significant.
Capsule determination
Planktonic cultures of BS68, BS71, BS72 and BS73 were
incubated with capsule-specific antiserum according to
supplier instructions (Statens Seruminstitut, Copenha-
gen, Denmark). For qualitative determination of pneu-
mococcal capsule, biofilms were rinsed, scraped and
incubated with type-specific capsule antibodies as for
planktonic cells. Additionally, 8 day biofilm cultures were
rinsed and examined in situ using CLSM after incubation
with polyclonal rabbit anti-capsular antibody and a sec-
ondary AffiniPure F(ab)2 fragment Texas Red-conjugated
donkey antirabbit IgG (H+L chain) antibody (Jackson
ImmunoResearch, West Grove, PA).
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